The DOI matches its Crossref record.
The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis
Abstract
BACKGROUND AND STUDY AIMS: The optimal approach for diagnosing sclerosing cholangitis remains unclear in the face of competing imaging technologies. We aimed to determine the most cost-effective strategy. PATIENTS AND METHODS: A decision model compared three approaches in the work-up of patients with suspected sclerosing cholangitis; all included an initial test, with, if unsuccessful, performance of a second cholangiographic method. They were magnetic resonance cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP), termed "MRCP_ERCP", ERCP and MRCP ("ERCP_MRCP"), or ERCP and a repeat ERCP ("ERCP_ERCP"). The implications of true and false positive and negative results with regard to costs and procedural complications were considered, including that of a liver biopsy, if indicated as a result of a negative work-up in the face of persistent clinical suspicion. The unit of effectiveness adopted was that of a correct diagnosis. Probability assumptions were derived from published literature, while cost estimates were derived from time-motion microanalyses or a national database, and expressed in Canadian dollars at 2004 values. Sensitivity analyses, including clinically relevant threshold analyses, were carried out. RESULTS: The average cost-effectiveness ratios were $414 for MRCP_ERCP, $1101 for ERCP_MRCP and $1123 for ERCP_ERCP, per correct diagnosis. The ERCP_MRCP strategy was dominated (more expensive and less effective) by MRCP_ERCP, while ERCP_ERCP was more effective and more costly than MRCP_ERCP, at $289,292 per additional correct diagnosis. Sensitivity and threshold analyses confirmed the robustness of these findings. CONCLUSIONS: Based on the model assumptions, a strategy of initial MRCP, followed, if negative, by ERCP is currently the most cost-effective approach to the work-up of patients with suspected sclerosing cholangitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advantages of MRCP over endoscopic retrograde cholangiopancreaticography (ERCP) include its noninvasive nature, lack of radiation use and lower cost, in addition to the potential to add MR elastography (MRE) for further information on disease staging and prognosis.28,29”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [29]
Citations
Cites
Still being checked.
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Larsen, S., Bendtzen, K., & Nielsen, O. H. (2010) · Annals of Medicine · doi:10.3109/07853890903559724 · Cited by 303
Dave, M., Elmunzer, B. J., Dwamena, B. A., & Higgins, P. D. R. (2010) · Radiology · doi:10.1148/radiol.10091953 · Cited by 265
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Schramm, C., Eaton, J. E., Ringe, K. I., Venkatesh, S. K., Yamamura, J., & for the MRI working group of the IPSCSG (2017) · Hepatology · doi:10.1002/hep.29293 · Cited by 158
Metadata
- Authors
- Meagher, S., Yusoff, I., Kennedy, W., Martel, M., Adam, V., & Barkun, A.
- Affiliations
- Montreal General Hospital (CA)
- UNSW Sydney (AU)
- ORCID
- Venue
- Endoscopy
- Publisher
- Georg Thieme Verlag KG
- Published
- 2007-03
- Volume
- 39
- Issue
- 3
- Pages
- 222-228
- ISSN
- 0013-726X (ISSN-L)
- 1438-8812
- OpenAlex
- W2048176301
- Cited by
- 50
- References
- 0
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endoscopy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- sclerosing cholangitis, magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography, diagnostic approach, cost-effectiveness, decision analysis, liver biopsy, diagnostic accuracy, cholangiography
- MeSH terms
- Adolescent, Adult, Aged, Cholangiopancreatography, Endoscopic Retrograde, Cost-Benefit Analysis, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Male, Middle Aged, Probability, Retrospective Studies, Sensitivity and Specificity, Reproducibility of Results, Cholangitis, Sclerosing, Models, Statistical, Cholangiopancreatography, Magnetic Resonance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. https://app.cochat.ai/papers/10.1055/s-2007-966253
- The paper
- Meagher, S., Yusoff, I., Kennedy, W., Martel, M., Adam, V., & Barkun, A. (2007). The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy. https://doi.org/10.1055/s-2007-966253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.